Inflammatory breast cancer: a new approach
Mené en France sur 101 patientes atteintes d'un cancer inflammatoire du sein HER2-, cet essai multicentrique de phase II évalue l'efficacité, du point de vue de la réponse pathologique complète, et la toxicité de l'ajout du bévacizumab à une chimiothérapie néoadjuvante et adjuvante
Breast cancers are the most common malignancies in women worldwide and are the second most common cause of death. Increased use of screening, dedicated research to improve understanding of the underlying biology of the disease, and the availability of new therapeutic agents have all contributed to the improved outcome of patients, especially in high-income countries. Inflammatory breast cancer is the most aggressive and deadly form of breast cancer and is frequently misdiagnosed and therefore considered a rare entity.
The Lancet Oncology , commentaire, 2015